Clinical Trial Update: Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety and immunogenicity of MAXVAX's recombinant herpes zoster vaccine produced in CHO cells in healthy adults 18 years and olde…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Recombinant Herpes Zoster Vaccine (CHO Cells) (recombinant herpes zoster vaccine produced in CHO cells)

Snippet

Sponsor: MAXVAX Biotechnology Limited Liability Company | Conditions: Herpes Zoster | Phase 1 | Status: ACTIVE_NOT_RECRUITING